Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Operating Expenses (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Other Operating Expenses data on record, last reported at $35065.0 in Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 60.49% year-over-year to $35065.0; the TTM value through Dec 2025 reached $225938.0, down 9.76%, while the annual FY2025 figure was $191106.0, 24.69% up from the prior year.
  • Other Operating Expenses reached $35065.0 in Q4 2025 per INM's latest filing, down from $110196.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $145839.0 in Q3 2022 and bottomed at -$8.8 million in Q2 2022.
  • Average Other Operating Expenses over 5 years is -$669007.9, with a median of $52294.5 recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: surged 411.14% in 2022, then crashed 200.79% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at -$4.2 million in 2021, then surged by 100.68% to $28812.0 in 2022, then plummeted by 200.79% to -$29040.0 in 2023, then surged by 405.6% to $88746.0 in 2024, then crashed by 60.49% to $35065.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $35065.0 in Q4 2025, $110196.0 in Q3 2025, and $18409.0 in Q2 2025.